GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » EV-to-EBIT

Vectus Biosystems (ASX:VBS) EV-to-EBIT : -0.55 (As of Jun. 23, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Vectus Biosystems's Enterprise Value is A$1.38 Mil. Vectus Biosystems's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-2.48 Mil. Therefore, Vectus Biosystems's EV-to-EBIT for today is -0.55.

The historical rank and industry rank for Vectus Biosystems's EV-to-EBIT or its related term are showing as below:

ASX:VBS' s EV-to-EBIT Range Over the Past 10 Years
Min: -22.1   Med: 0   Max: 0
Current: -0.55

ASX:VBS's EV-to-EBIT is ranked worse than
100% of 438 companies
in the Biotechnology industry
Industry Median: 8.76 vs ASX:VBS: -0.55

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Vectus Biosystems's Enterprise Value for the quarter that ended in Dec. 2023 was A$13.94 Mil. Vectus Biosystems's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-2.48 Mil. Vectus Biosystems's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -17.79%.


Vectus Biosystems EV-to-EBIT Historical Data

The historical data trend for Vectus Biosystems's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems EV-to-EBIT Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBIT
Get a 7-Day Free Trial -4.16 -8.09 -11.99 -12.26 -6.33

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -12.26 - -6.33 -

Competitive Comparison of Vectus Biosystems's EV-to-EBIT

For the Biotechnology subindustry, Vectus Biosystems's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vectus Biosystems's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vectus Biosystems's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vectus Biosystems's EV-to-EBIT falls into.



Vectus Biosystems EV-to-EBIT Calculation

Vectus Biosystems's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1.376/-2.48
=-0.55

Vectus Biosystems's current Enterprise Value is A$1.38 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vectus Biosystems's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-2.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vectus Biosystems  (ASX:VBS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Vectus Biosystems's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-2.48/13.94382
=-17.79 %

Vectus Biosystems's Enterprise Value for the quarter that ended in Dec. 2023 was A$13.94 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vectus Biosystems's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-2.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vectus Biosystems EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectus Biosystems (ASX:VBS) Business Description

Traded in Other Exchanges
N/A
Address
3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines